The Global Rise of China's Innovative Drugs: DengYue Medicine Empowers Industrial Overseas Expansion with Professional Distribution

When multinational giants such as Pfizer and GSK made successive moves in the first two days of 2026, acquiring product rights of Chinese innovative pharmaceutical companies for billions of US dollars, the global pharmaceutical industry clearly perceived a signal: China's innovative drugs have long bid farewell to "following and accompanying", officially becoming the "core supplier" in the global pharmaceutical market, and embarking on a leapfrog development from "quantitative growth" to "quality leadership".

As a key link connecting Chinese innovative pharmaceutical companies with the global terminal market, DengYue Medicine, relying on its accurate grasp of industry trends, has long laid out the global distribution of innovative drugs and become a core force empowering the overseas expansion of China's innovative drugs.

From the practical experience of deep cultivation in the industry for more than ten years, the rapid rise of China's innovative drugs in the global market is no accident. The four core advantages behind them have built a solid foundation for global competitiveness and also provided a broad service space for professional pharmaceutical wholesalers. The reason why Dengyue Pharmaceutical stands out in the industry lies in its precise alignment with the development characteristics of China's innovative drugs and the establishment of a full-chain distribution and supply chain service capability highly matched with them, enabling high-quality Chinese innovative drugs to move towards the global market efficiently, compliantly and stably.

I. The Global Rise of China's Innovative Drugs: Impressive Current Situation and Four Core Advantages Laying the Foundation for Overseas Expansion

Today, China's innovative drugs have entered a golden period of global development. They are no longer just "participants" in the global pharmaceutical market, but have become one of the "leaders". From R&D pipelines to clinical implementation, from product quality to compliance systems, the comprehensive strength of China's innovative drugs has been comprehensively improved. They not only fill many domestic gaps in clinical treatment, but also show unique advantages in the global market, laying a solid foundation for overseas distribution and putting forward higher requirements for the service capabilities of professional pharmaceutical wholesalers.

Advantage 1: Quality in Line with International Standards, "Zero Resistance" in Channel Promotion

The "high quality" of China's innovative drugs is no longer an empty slogan. With the continuous deepening of pharmaceutical review reforms, the review standards of NMPA (National Medical Products Administration) have been fully aligned with those of FDA and EMA. Major innovative drugs such as ADC, bispecific antibodies, PD-1 and GLP-1 not only benchmark against international first-line products in clinical data, but also have successively obtained recognition and approval from European and American drug regulatory authorities.

More notably, in 2025, the National Healthcare Security Administration released the first edition of the "Commercial Health Insurance Innovative Drug Catalog", which included 19 innovative drugs with high clinical value and urgent therapeutic needs, covering key areas such as oncology and rare diseases. This initiative not only enhanced the domestic recognition of China's innovative drugs, but also sent a signal to the world that "China's innovative drugs are trustworthy". This also requires pharmaceutical wholesalers to have professional qualification management and channel promotion capabilities. With its full-process compliance system and rich channel experience, Dengyue Pharmaceutical has become the preferred partner for undertaking the overseas demand of China's innovative drugs.

Advantage 2: Leading R&D and Supply Efficiency, Stable Supply "No Out-of-Stock"

In the global pharmaceutical market, "out-of-stock, supply interruption and long listing cycle" are the core pain points plaguing many wholesalers. For a popular innovative drug, the R&D and listing cycle in Europe and the United States often takes 8-10 years, while China's innovative drugs, relying on a complete R&D industrial chain and rich clinical resources, can shorten the R&D cycle to 5-6 years or even shorter.

At the same time, China has the most complete pharmaceutical production system in the world, and its large-scale production capacity can quickly respond to global market demand. The efficiency from R&D implementation to mass supply is far higher than that of similar products in Europe and the United States. Especially in 2026, China's innovative drugs have entered a harvest period. The down payment scale of BD transactions in the first one and a half months of the year exceeded one-third of the whole year of 2025. The continuous and stable supply of goods has put forward tests on the inventory management and supply chain response capabilities of wholesalers, and Dengyue Pharmaceutical's intelligent inventory and global distribution system is perfectly adapted to this demand.

Advantage 3: Prominent Cost-Effectiveness, Adapting to Global Multi-Level Medical Needs

On the premise of ensuring high quality, China's innovative drugs still have significant pricing advantages. Compared with European and American innovative drugs with annual treatment costs of hundreds of thousands of US dollars, China's innovative drugs have more inclusive pricing and stronger terminal accessibility.

They are not only suitable for mature European and American medical markets, but also can cover the needs of emerging medical markets such as Southeast Asia, the Middle East and Latin America, becoming an important supplement to the balanced allocation of global medical resources and promoting the continuous improvement of the global penetration rate of China's innovative drugs.

This characteristic of adapting to global multi-level medical needs requires pharmaceutical wholesalers to have extensive global channel coverage capabilities and localized service levels, and be able to provide customized distribution solutions according to the needs of different markets. With its channel network covering major global markets and localized service teams, Dengyue Pharmaceutical accurately connects medical needs in various regions and helps Chinese innovative drugs achieve widespread global landing.

Advantage 4: Improved Compliance System, "Smoother" Cross-Border Circulation

Compliance is the bottom line for pharmaceutical wholesale, especially for cross-border wholesale business, where compliance risks are even more critical. The overseas expansion of China's innovative drugs has already built a complete compliance system - every link, from international registration, clinical data mutual recognition to cross-border logistics and qualification filing, conforms to the norms of global pharmaceutical circulation.

At the same time, China has established pharmaceutical regulatory mutual recognition mechanisms with many countries and regions around the world. Coupled with the regional advantages of Hong Kong as a free trade port, the compliance threshold and time cost for cross-border circulation of innovative drugs have been greatly reduced. The efficiency and compliance of cross-border circulation are precisely the core advantages of Dengyue Pharmaceutical. With its professional compliance management and intelligent supply chain capabilities, we fully escort the cross-border circulation of China's innovative drugs and solve various problems in the process of overseas expansion.

In summary, relying on international-aligned quality, leading R&D and supply efficiency, cost-effectiveness adapting to global multi-level needs, and a complete compliance system, China's innovative drugs have gained a firm foothold in the global market and show a strong momentum of overseas expansion. The realization of these series of advantages is inseparable from the empowerment and support of professional pharmaceutical wholesalers. It not only requires wholesalers to accurately connect high-quality drug sources, but also needs to have comprehensive capabilities such as compliance management, global logistics and localized services - this is the core field where Dengyue Pharmaceutical has been deeply cultivating for many years, and also the confidence for us to go overseas with China's innovative drugs and build global competitiveness together.

II. Dengyue Pharmaceutical: Deeply Cultivating Innovative Drug Wholesale, Going Global with China's Innovative Drugs

The global rise of China's innovative drugs has brought unprecedented opportunities to wholesalers, but behind the opportunities, there are also challenges - how to connect high-quality innovative drug resources? How to solve the problems of cross-border logistics and compliance filing? How to quickly expand global channels?

As an enterprise focusing on global wholesale and supply chain services of innovative drugs, Dengyue Pharmaceutical (DengyueMed), with Hong Kong as its hub, has been deeply cultivating in the industry for many years and has already built a set of core competitiveness of "resources + capabilities + services". It can not only accurately grasp the advantages of China's innovative drugs, but also provide one-stop solutions for global partners, becoming the "core bridge" connecting Chinese innovative pharmaceutical companies with the global market.

1. Accurately Binding High-Quality Resources, Guaranteed Supply and Advantageous Prices

In terms of innovative drug resource connection, Dengyue Pharmaceutical has always adhered to "selecting the best from the best". We have established exclusive or priority distribution cooperation with leading Chinese innovative pharmaceutical companies such as BeiGene, Hengrui Medicine and荣昌 Biotech. At the same time, we keep up with the trend of BD transactions and connect with high-quality products of emerging Biotech companies such as Xianweida and Qianyan Biotech for the first time, covering key areas such as oncology, rare diseases, autoimmune diseases and metabolic diseases.

Relying on in-depth cooperative relations, we can not only obtain first-hand drug sources to ensure the stability of supply, but also get highly competitive purchase prices, enabling partners to have price advantages in the global market. At the same time, we have also established a complete inventory management system, which reasonably reserves goods according to the forecast of global market demand, avoids out-of-stock and supply interruption problems, and ensures that partners can place orders and pick up goods quickly at any time.

2. Full-Chain Compliance + Intelligent Supply Chain, "Zero Obstacle" in Cross-Border Circulation

Dengyue Pharmaceutical deeply understands that compliance and logistics are the "lifeblood" of cross-border innovative drug wholesale. We hold complete qualifications for pharmaceutical wholesale, import and export, and cold chain logistics, complying with Chinese and international GSP standards throughout the process.

At the same time, we have set up a professional compliance team focusing on policy research and compliance management, which can accurately interpret the drug regulatory policies and medical insurance policies of different countries and regions, and help partners avoid compliance risks.

In terms of logistics, we take Hong Kong as the global warehousing and distribution center, build an intelligent supply chain network covering major global markets such as Europe, America, Southeast Asia, the Middle East and Latin America, and equip professional cold chain transport vehicles and temperature control equipment to realize full-process temperature control monitoring and traceability of drugs from pharmaceutical factories to terminals. At the same time, we provide one-stop services such as customs clearance, local registration support and prescription circulation, greatly shortening the cross-border delivery cycle, ensuring the safe and timely delivery of innovative drugs, and solving the core pain points of wholesalers such as "difficult logistics and difficult customs clearance".

3. Digital Empowerment + Customized Services, More Than "Selling Drugs", But Also "Being Partners"

In the wave of digital transformation in the industry, Dengyue Pharmaceutical has abandoned the traditional wholesaler model of "only doing circulation, not providing services". Drawing on the advanced experience of digital circulation enterprises, it has built a self-developed data middle platform and intelligent management system, which can provide partners with data support such as market analysis, demand forecasting and channel planning, helping partners accurately grasp global market trends and optimize procurement and sales strategies.

More importantly, we provide full-process customized value-added services - assigning exclusive after-sales teams to provide pharmacovigilance, after-sales consultation and other services, and timely solving problems encountered by partners in the process of product use.

4. Relying on Hong Kong's Regional Advantages, More Convenient Capital and Trade

Dengyue Pharmaceutical takes Hong Kong as its operation hub and gives full play to the advantages of Hong Kong as a free trade port - convenient international settlement, free foreign exchange and high trade efficiency. It can quickly handle the capital settlement and trade processes of global cross-border pharmaceutical wholesale business, reduce capital occupation and improve business efficiency. At the same time, as an important hub for global pharmaceutical circulation, Hong Kong can quickly connect high-quality global channel resources, helping our partners quickly expand the global market and seize the opportunities of the times.

Dengyue Pharmaceutical accurately meets the needs of China's innovative drugs for global development. Based on the binding of high-quality innovative drug resources, supported by full-chain compliance and intelligent supply chain, and characterized by digital empowerment and customized services, it relies on Hong Kong's regional advantages to build a comprehensive global distribution service system for innovative drugs.

Seize the Opportunity of Innovative Drugs and Go to a Global New Future with Dengyue

From the total volume of China's innovative drug licensing transactions exceeding 135 billion US dollars in 2025 to the continuous boom in BD transactions at the beginning of 2026; from the recognition of China's innovative drugs by European and American drug regulatory authorities to the layout of China's innovative drug assets by global giants, the global breakthrough of China's innovative drugs has become an irreversible trend.

For pharmaceutical wholesalers, this is not a simple "opportunity of the times", but an opportunity for "transformation and upgrading" - abandoning the low-profit competition of traditional generic drugs and embracing the high-value track of China's innovative drugs can help them gain a firm foothold and achieve profit growth in the global pharmaceutical market.

DengYue Pharmaceutical has always resonated with China's innovative drugs at the same frequency. With high-quality innovative drug resources, professional compliance and logistics capabilities, and intimate customized services, it helps every partner seize the opportunities of the times and achieve win-win results. We firmly believe that China's innovative drugs will eventually rewrite the global pharmaceutical pattern, and Dengyue Pharmaceutical will become the "best partner" for every partner to deeply cultivate the global innovative drug market.

In the future, we will continue to deeply cultivate the innovative drug track, deepen cooperation with high-quality pharmaceutical companies, upgrade supply chain and service capabilities, and enable more high-quality Chinese innovative drugs to reach every corner of the world faster, more stably and more compliantly through our channels, bringing new treatment hopes to global patients and creating greater commercial value for our partners.